IncobotulinumtoxinA: A Review in Upper Limb Spasticity
- 383 Downloads
Intramuscular incobotulinumtoxinA (Xeomin®) is indicated for the treatment or improvement of adult patients with upper limb spasticity (featured indication), cervical dystonia, blepharospasm and glabellar lines. It is a highly purified formulation of botulinum toxin type A that inhibits acetylcholine signalling at neuromuscular junctions, reducing muscle hypertonia. This narrative review discusses the clinical use of incobotulinumtoxinA in adults with upper limb spasticity and summarizes its pharmacological properties. In single-treatment phase 3 trials, compared with placebo, incobotulinumtoxinA treatment improved muscle tone, global spasticity, functional spasticity-related disability and some aspects of carer burden in adults with upper limb spasticity. These beneficial effects of incobotulinumtoxinA on muscle tone were generally maintained in extension studies, in which up to five additional incobotulinumtoxinA treatments were administered. Functional spasticity-related disability and carer burden were also reduced during longer-term incobotulinumtoxinA treatment. IncobotulinumtoxinA was generally well tolerated in clinical trials, with relatively few patients experiencing treatment-related adverse events, most of which were of mild to moderate intensity. No neutralizing antibodies that would potentially cause secondary nonresponse against incobotulinumtoxinA were detected after single and multiple treatments in these trials or in phase 3 and 4 trials of incobotulinumtoxinA in other indications, which may be an advantage of this purified formulation. Further research would help to more fully determine the impact of neurotoxin purification in terms of reducing the potential risk of immunogenic responses during long-term treatment. Hence, incobotulinumtoxinA is a useful treatment option for upper limb spasticity in adult patients.
KeywordsTarget Domain Elbow Flexor Cervical Dystonia onabotulinumtoxinA Wrist Flexor
During the peer review process, the manufacturer of incobotulinumtoxinA was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Yvette Lamb and Lesley Scott are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
- 12.Blümel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotox Res. 2006;9(2–3):238.Google Scholar
- 14.Merz Pharmaceuticals LLC. Xeomin (incobotulinumtoxinA) for injection, for intramuscular use: US prescribing information. 2015. http://www.xeomin.com/. Accessed 11 Aug 2016.
- 15.Merz Pharma UK Ltd. Xeomin 100 units: summary of product characteristics. 2014. http://www.medicines.org.uk/. Accessed 11 Aug 2016.
- 19.Elovic E, Munin MC, Kaňovský P, et al. Efficacy and safety of repeated incobotulinumtoxinA injections for upper-limb post-stroke spasticity [abstract]. In: Annual Assembly of the AAPM&R. 2015.Google Scholar